28 March 2024 : Clinical Research
Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Predicting Complete Pathological Response in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy
Mustafa Karaca
1ACDEF, Ece Salim2ABDEF, Mustafa Serkan Alemdar 3BDEF, Özge Deniz Karaca 2BEF, Mustafa Özgür Arıcı 3BDEF*
DOI: 10.12659/MSM.943750
Med Sci Monit 2024; 30:e943750
Table 4 Patient characteristics according to pathological response.
| Variables | Complete response (n=34) | Near-complete response (n=61) | Partial response (n=68) | No response (n=24) | p |
|---|---|---|---|---|---|
| Age (years)* | 65.38±11.11 | 66.79±10.55 | 62.75±11.8 | 63.08±10.65 | 0.188 |
| Gender** | |||||
| Male | 25 (73.5) | 35 (57.4) | 45 (66.2) | 18 (75) | 0.292 |
| Female | 9 (26.5) | 26 (42.6) | 23 (33.8) | 6 (25) | |
| Comorbid disease** | 10 (29.4) | 26 (42.6) | 27 (39.7) | 12 (50) | 0.430 |
| Diabetes mellitus | 4 (11.8) | 12 (19.7) | 14 (20.6) | 7 (29.2) | 0.434 |
| Hypertension | 0 (0) | 2 (3.3) | 0 (0) | 0 (0) | 0.375 |
| Ulcerative colitis | 6 (17.6) | 12 (19.7) | 11 (16.2) | 5 (20.8) | 0.941 |
| CAD | 0 (0) | 0 (0) | 2 (2.9) | 0 (0) | 0.628 |
| Chemotherapy agent** | |||||
| Capecitabine | 19 (55.9) | 35 (57.4) | 32 (47.1) | 10 (41.7) | 0.463 |
| 5-FU | 15 (44.1) | 26 (42.6) | 36 (52.9) | 14 (58.3) | |
| Type of surgery** | |||||
| LAR | 30 (88.2) | 49 (80.3) | 57 (83.8) | 18 (75) | 0.577 |
| MILES operation | 4 (11.8) | 12 (19.7) | 11 (16.2) | 6 (25) | |
| Hemoglobin at diagnosis* | 13.06±1.81 | 12.47±1.73 | 12.18±2.28 | 12.53±2.5 | 0.247 |
| Neutrophils at diagnosis*** | 5 (3.9–6) | 4.6 (3.8–6) | 5.5 (4.15–6.3) | 5.3 (4.35–6.9) | 0.198 |
| Lymphocytes at diagnosis*** | 1.85 (1.4–2.2) | 1.9 (1.5–2.4) | 1.9 (1.4–2.3) | 1.65 (1.4–2.1) | 0.580 |
| Platelets at diagnosis*** | 275 (206–353) | 287 (239–327) | 287.5 (239.5–337.5) | 261 (235.5–349.5) | 0.903 |
| LDH at diagnosis*** | 190.5 (174–222) | 194 (163–235) | 188 (162.5–220) | 194 (160–230) | 0.756 |
| NLR at diagnosis | 2.93 (1.8–3.67) | 2.43 (2.06–3.13) | 3.06 (2.16–3.98) | 3.29 (2.07–4.07) | 0.127 |
| >3.63 | 9 (26.5) | 9 (14.8) | 22 (32.4) | 10 (41.7) | |
| Results are presented as * mean±SD, ** n (%), *** median (IQR). One-way ANOVA, Kruskal-Wallis test, Pearson chi-square test, Fisher’s Exact test. The same lowercase letters in a row indicate that there is no significant difference between the groups. CAD – coronary artery disease; 5-FU – 5-Fluorouracil; LAR – low anterior resection; LDH – lactate dehydrogenase; NLR – neutrophil/lymphocyte ratio. The same lowercase letters in a row indicate that there is no significant difference between the groups. | |||||